Working… Menu

Evaluation of the Safety of and Immune Response to an HIV Vaccine in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00051454
Recruitment Status : Completed
First Posted : January 13, 2003
Last Update Posted : August 27, 2007
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:
This study will examine the safety and immune response to a two-part HIV vaccine. Healthy volunteers who are at low risk of HIV infection will receive either active vaccine or a placebo.

Condition or disease Intervention/treatment Phase
HIV Infections Biological: HIV DNA plasmid vaccine plus recombinant fowlpox vector Phase 1 Phase 2

Detailed Description:

The purpose of this study is to examine the safety and immunogenicity of a candidate vaccine strategy for HIV prophylaxis using a DNA-prime plus recombinant fowlpox boost. The DNA plasmid and fowlpox vector contain HIV genes. However, these vaccines contain only some HIV genes and cannot themselves cause HIV or AIDS.

Eligible volunteers at low risk of HIV infection will be randomized to receive either active vaccine or placebo injections at Day 0, Week 4, and Week 8. Intensive immunologic and safety monitoring will be done during the first 16 weeks of the study. Follow-up will continue to Week 52.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: A Randomised, Placebo-Controlled, Double-Blind, Phase I/IIa Clinical Trial to Evaluate the Safety and Immunogenicity of a Candidate Prophylactic DNA Prime-rFPV Boost HIV Vaccination Strategy
Study Start Date : March 2003
Study Completion Date : February 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Primary Outcome Measures :
  1. Safety and adverse events among the two vaccination groups
  2. lymphoproliferative (LP) responses to HIV antigens, as assessed by LP assays at Week 9
  3. CD8+ T cell responses to HIV antigens, as assessed by ELIspot assay of interferon gamma (IFN-g) secreting cells at Week 9

Secondary Outcome Measures :
  1. Proportion of patients with positive LP assay and ELISPOT assay responses
  2. intracellular cytokine staining (ICS) of IFN-g/CD69 and flow cytometry
  3. 51-Cr release cytotoxic T cell lymphocyte assay
  4. HLA class I tetramer analyses
  5. anti-HIV gag, pol and env antibodies, as assessed by ELISA and Western blot
  6. behavioral changes in study participants

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

  • HIV negative.
  • Acceptable methods of contraception.

Exclusion Criteria

  • Identifiable risk behavior for HIV infection, including: sexual partners of HIV positive people, sexual intercourse with a partner of unknown HIV status if that partner is reported to be at higher risk for HIV infection, gay men reporting any unprotected anal intercourse with partners of unknown status in the 12 months preceding study entry, individuals diagnosed with a sexually transmissible infection (STI) in the 12 months preceding entry that may have been acquired through anal or vaginal intercourse, individuals reporting sharing of injecting equipment in the last 12 months.
  • HIV candidate vaccines in a previous HIV vaccine trial.
  • Live attenuated vaccines within 60 days prior to entering the study. Whole killed, toxoid, or sub-unit vaccines (e.g., influenza, pneumococcal, tetanus, and hepatitis B) are not exclusionary within 4 weeks prior to the scheduled experimental HIV vaccines.
  • Hypersensitivity to egg products or a known history of anaphylaxis or any other serious adverse reactions to vaccination.
  • History of serious allergic reaction requiring hospitalization or emergency medical care (e.g., Stevens-Johnson syndrome, bronchospasm, or hypotension) to any substance.
  • Significant illness requiring immunomodulatory or cytotoxic therapy.
  • History of cancer unless there is evidence of surgical excision followed by a sufficient observation period to give a reasonable assurance of cure.
  • Blood products or immunoglobulins within 6 months prior to entering the study.
  • Experimental or investigational agents within 30 days prior to entering the study.
  • Recreational and/or therapeutic drug use that might compromise the study participant's safety.
  • Medical or psychiatric condition or occupational responsibilities that preclude compliance with the protocol.
  • Pregnant or lactating women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00051454

Layout table for location information
Australia, New South Wales
National Centre in HIV Epidemiology and Clinical Research
Sydney, New South Wales, Australia, 2010
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Layout table for investigator information
Study Director: David A Cooper, MD, DSc National Centre in HIV Epidemiology and Clinical Research, University of New South Wales
Additional Information:
Publications of Results:
Layout table for additonal information Identifier: NCT00051454    
Other Study ID Numbers: N01-AI05395
First Posted: January 13, 2003    Key Record Dates
Last Update Posted: August 27, 2007
Last Verified: August 2007
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
HIV Seronegativity
HIV Preventive Vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases